ALK-Abelló A/S narrowed the revenue guidance for the full year 2023. For the period, the company expected revenue to grow by 8% to 10% organically in local currencies (previously: 7% to 11%), which is equivalent to 9% to 11% growth, disregarding the one-year temporary mandatory rebate increase for prescription drugs in Germany.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130 DKK | +4.50% | +3.50% | +28.46% |
Mar. 14 | Transcript : ALK-Abelló A/S - Shareholder/Analyst Call | |
Mar. 04 | New entries in MarketScreener's Europe portfolio |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.46% | 4.12B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ALK B Stock
- News ALK-Abelló A/S
- ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023